Affiliations 

  • 1 Health and Safety Department, Dubai Municipality, Dubai, UAE
  • 2 Pharmacy Department, Emirates Health Services, Dubai, UAE
  • 3 Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, UAE
  • 4 Clinical Science Department, College of Medicine, University of Sharjah, Sharjah, UAE
  • 5 Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, UAE
  • 6 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
  • 7 Department of Mathematics and Sciences, Ajman University, Ajman, UAE
  • 8 Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia
Am J Mens Health, 2023;17(2):15579883231158531.
PMID: 36987378 DOI: 10.1177/15579883231158531

Abstract

Sexual enhancement supplements (SESs) that have illegal additions of pharmaceuticals or analogues pose a significant health risk, particularly with long-term usage. When supplements are adulterated with phosphodiesterase type 5 (PDE-5) inhibitors, dosages can vary widely and there may be an increase in adverse effects and drug-drug interactions which cannot be avoided. Consequently, there is a need to evaluate the public risk awareness toward SES and the associated adverse events as well as explore significant factors associated with knowledge and risk awareness. A cross-sectional community-based study was conducted among University male students and staff at Ajman University, United Arab Emirates (UAE), using a self-administered survey via a web-based electronic link to explore key issues. A total of 1,101 male subjects participated in the study and completed the questionnaire. Four hundred and thirty-three(39.3%) (95% confidence interval [CI]: 33.2-44.5) participants reported using SES products. Of these, 137 (31.6%) [95% CI: 28.6-37.2] experienced adverse effects from SES product use. SES use was more prevalent among participants aged 60 to 69 years (odds ratio [OR]: 2.94; 95% CI: 1.63-5.28), diabetic patients (OR: 2.61; 95% CI: 1.75-3.90), hypertension patients (OR: 2.12; 95% CI: 1.45-3.1), and those overweight or obese (OR: 1.84; 95% CI: 1.44-2.35). This study indicates that SES is a popular practice among the UAE university staff and students. However, there is a need to implement risk awareness programs to raise public awareness regarding SES use and safety. Regulatory bodies are encouraged to provide additional advice on the proper use and possible risks of consuming SES.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.